Cargando…
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is lim...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/ https://www.ncbi.nlm.nih.gov/pubmed/28420120 http://dx.doi.org/10.3390/ijms18040837 |
_version_ | 1783232998203719680 |
---|---|
author | Almeida, Antonio M. Prebet, Thomas Itzykson, Raphael Ramos, Fernando Al-Ali, Haifa Shammo, Jamile Pinto, Ricardo Maurillo, Luca Wetzel, Jaime Musto, Pellegrino Van De Loosdrecht, Arjan A. Costa, Maria Joao Esteves, Susana Burgstaller, Sonja Stauder, Reinhard Autzinger, Eva M. Lang, Alois Krippl, Peter Geissler, Dietmar Falantes, Jose Francisco Pedro, Carmen Bargay, Joan Deben, Guillermo Garrido, Ana Bonanad, Santiago Diez-Campelo, Maria Thepot, Sylvain Ades, Lionel Sperr, Wolfgang R. Valent, Peter Fenaux, Pierre Sekeres, Mikkael A. Greil, Richard Pleyer, Lisa |
author_facet | Almeida, Antonio M. Prebet, Thomas Itzykson, Raphael Ramos, Fernando Al-Ali, Haifa Shammo, Jamile Pinto, Ricardo Maurillo, Luca Wetzel, Jaime Musto, Pellegrino Van De Loosdrecht, Arjan A. Costa, Maria Joao Esteves, Susana Burgstaller, Sonja Stauder, Reinhard Autzinger, Eva M. Lang, Alois Krippl, Peter Geissler, Dietmar Falantes, Jose Francisco Pedro, Carmen Bargay, Joan Deben, Guillermo Garrido, Ana Bonanad, Santiago Diez-Campelo, Maria Thepot, Sylvain Ades, Lionel Sperr, Wolfgang R. Valent, Peter Fenaux, Pierre Sekeres, Mikkael A. Greil, Richard Pleyer, Lisa |
author_sort | Almeida, Antonio M. |
collection | PubMed |
description | Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL. |
format | Online Article Text |
id | pubmed-5412421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54124212017-05-05 Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study Almeida, Antonio M. Prebet, Thomas Itzykson, Raphael Ramos, Fernando Al-Ali, Haifa Shammo, Jamile Pinto, Ricardo Maurillo, Luca Wetzel, Jaime Musto, Pellegrino Van De Loosdrecht, Arjan A. Costa, Maria Joao Esteves, Susana Burgstaller, Sonja Stauder, Reinhard Autzinger, Eva M. Lang, Alois Krippl, Peter Geissler, Dietmar Falantes, Jose Francisco Pedro, Carmen Bargay, Joan Deben, Guillermo Garrido, Ana Bonanad, Santiago Diez-Campelo, Maria Thepot, Sylvain Ades, Lionel Sperr, Wolfgang R. Valent, Peter Fenaux, Pierre Sekeres, Mikkael A. Greil, Richard Pleyer, Lisa Int J Mol Sci Article Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3–9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p ≤ 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL. MDPI 2017-04-14 /pmc/articles/PMC5412421/ /pubmed/28420120 http://dx.doi.org/10.3390/ijms18040837 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Almeida, Antonio M. Prebet, Thomas Itzykson, Raphael Ramos, Fernando Al-Ali, Haifa Shammo, Jamile Pinto, Ricardo Maurillo, Luca Wetzel, Jaime Musto, Pellegrino Van De Loosdrecht, Arjan A. Costa, Maria Joao Esteves, Susana Burgstaller, Sonja Stauder, Reinhard Autzinger, Eva M. Lang, Alois Krippl, Peter Geissler, Dietmar Falantes, Jose Francisco Pedro, Carmen Bargay, Joan Deben, Guillermo Garrido, Ana Bonanad, Santiago Diez-Campelo, Maria Thepot, Sylvain Ades, Lionel Sperr, Wolfgang R. Valent, Peter Fenaux, Pierre Sekeres, Mikkael A. Greil, Richard Pleyer, Lisa Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |
title | Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |
title_full | Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |
title_fullStr | Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |
title_full_unstemmed | Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |
title_short | Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |
title_sort | clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: a retrospective multinational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412421/ https://www.ncbi.nlm.nih.gov/pubmed/28420120 http://dx.doi.org/10.3390/ijms18040837 |
work_keys_str_mv | AT almeidaantoniom clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT prebetthomas clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT itzyksonraphael clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT ramosfernando clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT alalihaifa clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT shammojamile clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT pintoricardo clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT maurilloluca clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT wetzeljaime clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT mustopellegrino clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT vandeloosdrechtarjana clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT costamariajoao clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT estevessusana clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT burgstallersonja clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT stauderreinhard clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT autzingerevam clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT langalois clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT kripplpeter clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT geisslerdietmar clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT falantesjosefrancisco clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT pedrocarmen clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT bargayjoan clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT debenguillermo clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT garridoana clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT bonanadsantiago clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT diezcampelomaria clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT thepotsylvain clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT adeslionel clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT sperrwolfgangr clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT valentpeter clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT fenauxpierre clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT sekeresmikkaela clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT greilrichard clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy AT pleyerlisa clinicaloutcomesof217patientswithacuteerythroleukemiaaccordingtotreatmenttypeandlinearetrospectivemultinationalstudy |